Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models

International Immunopharmacology

Volumn 9, Issue 1, 2009, Pages 55-62

  Harada, Daisuke ^a   Takada, Chie ^a   Nosaka, Yukino ^a   Takashima, Yuko ^a   Kobayashi, Katsuya ^a   Takaba, Katsumi ^a   Manabe, Haruhiko ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

2,4,6 trinitro 1 chlorobenzene; Atopic dermatitis; KF66490; NC Nga; Phosphodiesterase 4; Rolipram

Indexed keywords

4 CYANO 4 (2,3 DIHYDRO 8 METHOXY 1,4 BENZODIOXIN 5 YL)CYCLOHEXANECARBOXYLIC ACID; DEXAMETHASONE; FINGOLIMOD; INTERLEUKIN 1BETA; INTERLEUKIN 4; KF 66490; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PICRYL CHLORIDE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG EFFICACY; FIBROBLAST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INFLAMMATION; T LYMPHOCYTE; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOHEXANECARBOXYLIC ACIDS; CYTOKINES; DERMATITIS, CONTACT; DIOXANES; EAR, EXTERNAL; IMMUNOGLOBULIN E; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; INTERLEUKIN-4; MALE; MICE; MICE, INBRED BALB C; PHOSPHODIESTERASE INHIBITORS; PICRYL CHLORIDE; PREDNISOLONE; VOMITING;

EID: 58149459461     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.09.011     Document Type: Article

References (47)

1. Cooper K.D. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 102 (1994) 128-137
2. Rudikoff D., and Lebwohl M. Atopic dermatitis. Lancet 351 (1998) 1715-1721
3. Soter N.A. Morphology of atopic eczema. Allergy 44 (1989) 16-19
4. Uehara M., Izukura R., and Sawai T. Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol 15 (1990) 264-266
5. Williams H., and Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol 118 (2006) 209-213
6. Akhavan A., and Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 24 (2003) 225-240
7. Pua V.S., and Barnetson R.S. Recent developments in the treatment of adult atopic dermatitis. Australas J Dermatol 47 (2006) 84-89
8. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65 (2001) 1-52
9. Butler J.M., Chan S.C., Stevens S., and Hanifin J.M. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 71 (1983) 490-497
10. Grewe S.R., Chan S.C., and Hanifin J.M. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 70 (1982) 452-457
11. Safko M.J., Chan S.C., Cooper K.D., and Hanifin J.M. Heterologous desensitization of leukocytes: a possible mechanism of beta adrenergic blockade in atopic dermatitis. J Allergy Clin Immunol 68 (1981) 218-225
12. Hanifin J.M., and Chan S.C. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 105 (1995) 84S-88S
13. Chujor C.S., Hammerschmid F., and Lam C. Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epidermoid cell lines. J Invest Dermatol 110 (1998) 287-291
14. Cooper K.D., Kang K., Chan S.C., and Hanifin J.M. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 84 (1985) 477-482
15. Dent G., Giembycz M.A., Evans P.M., Rabe K.F., and Barnes P.J. Suppression of human eosinophil respiratory burst end cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther 271 (1994) 1167-1174
16. Gantner F., Kupferschmidt R., Schudt C., Wendel A., and Hatzelmann A. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 121 (1997) 221-231
17. Hanifin J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson Jr. W.R., Kirby D.S., et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107 (1996) 51-56
18. Griffiths C.E., Van Leent E.J., Gilbert M., and Traulsen J. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 147 (2002) 299-307
19. Fujii Y., Takeuchi H., Tanaka K., Sakuma S., Ohkubo Y., and Mutoh S. Effects of FK506 (tacrolimus hydrate) on chronic oxazolone-induced dermatitis in rats. Eur J Pharmacol 456 (2002) 115-121
20. Griswold D.E., Webb E.F., Badger A.M., Gorycki P.D., Levandoski P.A., Barnette M.A., et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 287 (1998) 705-711
21. Hanifin J.M., and Chan S.C. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 41 (1999) 72-77
22. Inoue Y., Isobe M., Shiohara T., Goto Y., and Hayashi H. Protective and curative effects of topically applied CX-659S, a novel diaminouracil derivative, on chronic picryl chloride-induced contact hypersensitivity responses. Br J Dermatol 147 (2002) 675-682
23. Matsuda H., Watanabe N., Geba G.P., Sperl J., Tsudzuki M., Hiroi J., et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9 (1997) 461-466
24. Vestergaard C., Yoneyama H., Murai M., Nakamura K., Tamaki K., Terashima Y., et al. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 104 (1999) 1097-1105
25. Vestergaard C., Yoneyama H., and Matsushima K. The NC/Nga mouse: a model for atopic dermatitis. Mol Med Today 6 (2000) 209-210
26. Harada D., Takada C., Tsukumo Y., Takaba K., and Manabe H. Analyses of a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. J Dermatol Sci 37 (2005) 159-167
27. Harada D., Tsukumo Y., Takashima Y., and Manabe H. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. Eur J Pharmacol 532 (2006) 128-137
28. Kawamoto T., and Shimizu M. A method for preparing 2- to 50-micro-thick fresh-frozen sections of large samples and undecalcified hard tissues. Histochem Cell Biol 113 (2000) 331-339
29. Andrews P.L., Okada F., Woods A.J., Hagiwara H., Kakaimoto S., and Toyoda M. The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol 130 (2000) 1247-1254
30. Crocker I.C., Townley R.G., and Khan M.M. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 31 (1996) 223-235
31. Elbe-Burger A., Egyed A., Olt S., Klubal R., Mann U., Rappersberger K., et al. Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol 118 (2002) 767-778
32. Kitajima T., Ariizumi K., Mohamadazadeh M., Edelbaum D., Bergstresser P.R., and Takashima A. T cell-dependent secretion of IL-1 beta by a dendritic cell line (XS52) derived from murine epidermis. J Immunol 155 (1995) 3794-3800
33. Kitagaki H., Ono N., Hayakawa K., Kitazawa T., Watanabe K., and Shiohara T. Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile. J Immunol 159 (1997) 2484-2491
34. Atamas S.P., Luzina I.G., Dai H., Wilt S.G., and White B. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 168 (2002) 1139-1145
35. Tsudzuki M., Watanabe N., Wada A., Nakane Y., Hiroi J., and Matsuda H. Genetic analyses for dermatitis and IgE hyperproduction in the NC/Nga mouse. Immunogenetics 47 (1997) 88-90
36. Hashimoto Y., Kaneda Y., Takahashi N., Akashi S., Arai I., and Nakaike S. Clarithromycin inhibits the development of dermatitis in NC/Nga mice. Chemotherapy 49 (2003) 222-228
37. Hiroi J., Sengoku T., Morita K., Kishi S., Sato S., Ogawa T., et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol 76 (1998) 175-183
38. Kohno T., Tsuji T., Hirayama K., Watabe K., Matsumoto A., Kohno T., et al. A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice. Biol Pharm Bull 27 (2004) 1392-1396
39. Nakamura H., Aoki M., Tamai K., Oishi M., Ogihara T., Kaneda Y., et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 9 (2002) 1221-1229
40. Sanz M.J., Cortijo J., and Morcillo E.J. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 106 (2005) 269-297
41. Aioi A., Tonogaito H., Suto H., Hamada K., Ra C., Ogawa H., et al. Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis. Br J Dermatol 144 (2001) 12-18
42. Yagi R., Nagai H., Iigo Y., Akimoto T., Arai T., and Kubo M. Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. J Immunol 168 (2002) 2020-2027
43. Horikoshi K., Yokoyama T., Kishibayashi N., Ohmori K., Ishii A., and Karasawa A. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus. Jpn J Pharmacol 85 (2001) 70-74
44. Gardner C., and Perren M. Inhibition of anaesthetic-induced emesis by a NK1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus. Neuropharmacology 37 (1998) 1643-1644
45. Sawanishi H., Suzuki H., Yamamoto S., Waki Y., Kasugai S., Ohya K., et al. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines. J Med Chem 40 (1997) 3248-3253
46. Sidbury R., and Hanifin J.M. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 25 (2000) 559-566
47. Bäumer W., Hoppmann J., Rundfeldt C., and Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 6 (2007) 17-26